Advertisement
Advertisement
VTVT
vTv Therapeutics Inc. Class A Common Stock
35.37
USDSponsored
+0.76
+2.20%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
35.17
-0.20
-0.56%
VTVT Earnings Reports
Positive Surprise Ratio
VTVT beat 23 of 36 last estimates.
64%
Next Report
Today
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$306.00K
/-$1.00
Implied change from Q1 26 (Revenue/ EPS)
-99.17%
/-151.55%
Implied change from Q2 25 (Revenue/ EPS)
--
/+8.70%
vTv Therapeutics Inc. Class A Common Stock earnings per share and revenue
On May 13, 2026, VTVT reported earnings of 1.94 USD per share (EPS) for Q1 26, beating the estimate of -0.09 USD, resulting in a 2102.06% surprise. Revenue reached 36.84 million, compared to an expected 20.40 million, with a 80.58% difference. The market reacted with a +21.36% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -1.00 USD, with revenue projected to reach 306.00 thousand USD, implying an decrease of -151.55% EPS, and decrease of -99.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were vTv Therapeutics Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, vTv Therapeutics Inc. Class A Common Stock reported EPS of $1.94, beating estimates by 2102.06%, and revenue of $36.84M, 80.58% above expectations.
How did the market react to vTv Therapeutics Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 21.36%, changed from $31.66 before the earnings release to $38.43 the day after.
When is vTv Therapeutics Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for vTv Therapeutics Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, vTv Therapeutics Inc. Class A Common Stock is expected to report EPS of -$1.00 and revenue of $306.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement